CATALOGO DEI PRODOTTI DELLA RICERCA

BRONTE, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.990
NA - Nord America 8.983
AS - Asia 6.302
SA - Sud America 923
AF - Africa 116
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 5
Totale 26.347
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.858
RU - Federazione Russa 3.452
GB - Regno Unito 2.878
SG - Singapore 2.783
CN - Cina 1.816
IT - Italia 776
BR - Brasile 751
HK - Hong Kong 750
DE - Germania 612
FI - Finlandia 530
FR - Francia 527
IE - Irlanda 439
SE - Svezia 353
VN - Vietnam 331
KR - Corea 206
UA - Ucraina 140
NL - Olanda 81
IN - India 73
TR - Turchia 67
CA - Canada 66
AR - Argentina 65
ID - Indonesia 61
JP - Giappone 47
ZA - Sudafrica 39
AT - Austria 37
MX - Messico 36
ES - Italia 34
BE - Belgio 30
EC - Ecuador 30
BD - Bangladesh 29
PL - Polonia 25
AU - Australia 19
CO - Colombia 19
MA - Marocco 16
PK - Pakistan 16
IQ - Iraq 14
PY - Paraguay 13
SA - Arabia Saudita 12
VE - Venezuela 12
CZ - Repubblica Ceca 11
EG - Egitto 10
PE - Perù 10
UZ - Uzbekistan 10
TG - Togo 9
AE - Emirati Arabi Uniti 8
AL - Albania 8
BJ - Benin 8
KE - Kenya 8
NZ - Nuova Zelanda 8
AZ - Azerbaigian 7
BO - Bolivia 7
CL - Cile 7
OM - Oman 7
TN - Tunisia 7
UY - Uruguay 7
TW - Taiwan 6
BY - Bielorussia 5
CR - Costa Rica 5
IL - Israele 5
IR - Iran 5
JM - Giamaica 5
LT - Lituania 5
LV - Lettonia 5
MY - Malesia 5
PH - Filippine 5
AM - Armenia 4
DK - Danimarca 4
DZ - Algeria 4
HU - Ungheria 4
JO - Giordania 4
LB - Libano 4
MK - Macedonia 4
NP - Nepal 4
RO - Romania 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
EE - Estonia 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
NG - Nigeria 3
SK - Slovacchia (Repubblica Slovacca) 3
AD - Andorra 2
BG - Bulgaria 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
KW - Kuwait 2
LK - Sri Lanka 2
PA - Panama 2
PS - Palestinian Territory 2
SI - Slovenia 2
SO - Somalia 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 26.322
Salva come PNG Salva come JPEG
Città #
Southend 2.673
Singapore 1.355
Jacksonville 1.243
Moscow 1.049
Chandler 857
Woodbridge 851
Hong Kong 737
Dallas 722
Ashburn 719
Ann Arbor 635
Houston 441
Dublin 427
Verona 377
Beijing 297
The Dalles 223
Lawrence 220
Princeton 220
Wilmington 218
Los Angeles 193
Munich 171
New York 160
Helsinki 134
Nanjing 132
Shenyang 119
Jinan 115
Buffalo 96
Ho Chi Minh City 95
Sindelfingen 84
Columbus 80
Tianjin 77
Redmond 75
Redondo Beach 67
Hebei 66
Milan 65
São Paulo 59
Hanoi 57
Nanchang 55
Haikou 51
Ningbo 49
Hangzhou 48
San Francisco 48
Zhengzhou 47
Changsha 44
Santa Clara 44
Jakarta 42
Guangzhou 40
Seattle 38
Tokyo 38
Chicago 36
Jiaxing 35
Taizhou 34
London 32
Turku 32
Norwalk 31
Brooklyn 29
Brussels 29
Seoul 29
Nuremberg 28
Stockholm 28
Toronto 28
Dong Ket 27
Council Bluffs 26
Amsterdam 25
Boardman 25
Phoenix 25
Taiyuan 25
Johannesburg 23
Redwood City 22
Rio de Janeiro 22
Dearborn 20
Dongguan 20
Fuzhou 20
Boston 19
Brasília 19
Falls Church 19
Vienna 19
Denver 18
Warsaw 18
Washington 18
Atlanta 17
Belo Horizonte 17
Chennai 17
Frankfurt am Main 17
Haiphong 17
Orem 16
Grafing 15
Lappeenranta 15
Montreal 15
Fairfield 13
Quito 13
Ankara 12
Falkenstein 12
Da Nang 11
Düsseldorf 11
Lanzhou 11
Mexico City 11
San Jose 11
Cambridge 10
Campinas 10
Hải Dương 10
Totale 16.715
Salva come PNG Salva come JPEG
Nome #
IFN-gamma- Mediated Upmodulation of MHC Class I Expression Activates Tumor-Specific Immune Response in a Mouse Model of Prostate Cancer 278
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 274
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 258
IFN-gamma- Mediated Upmodulation of MHC Class I Expression Associated to a B7-1-Expressing Tumor Cell Vaccine Activates Tumor-Specific Immune Response in a Mouse Model of Prostate Cancer. 253
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma 227
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 224
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 221
Deciphering the state of immune silence in fatal COVID-19 patients 208
Unraveling the role of lymph node metastasis in PDAC and dCCA progression 207
Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy 199
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. 196
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. 195
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 195
Baricitinib restrains the immune dysregulation in patients with severe COVID-19 194
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 193
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 191
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer 186
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 183
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 183
Altered macrophage differentiation and immune dysfunction in tumor development. 182
Antigen specificity of immune suppression by myeloid-derived suppressor cells. 178
Disabled homolog 2 controls pro-metastatic activity of tumor-associated macrophages 175
Antitumor vaccination: where we stand. 173
Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. 171
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. 169
Human Anti Cancer Cytokine Induced Killer Cells and TheirInteraction With the Host Immune System 168
Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis 168
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). 166
Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins 166
Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression 166
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 166
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. 164
Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice bearing lung metastases. 162
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. 161
Role of P2z purinergic receptors in ATP-mediated killing of tumor necrosis factor (TNF)-sensitive and TNF-resistant L929 fibroblasts. 159
Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC 157
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. 157
A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells 157
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer 155
The Emerging Immunological Role of Post-Translational Modifications by Reactive Nitrogen Species in Cancer Microenvironment 154
The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia 154
4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells 153
MDSCs in cancer: Conceiving new prognostic and therapeutic targets 152
Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. 151
mTOR and STAT3 Pathway Hyper-Activation is Associated with evated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment 151
The Endless Saga of Monocyte Diversity 145
Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+Monocytic Antigen-Presenting Cells in Tumors 144
Platelets promote thromboinflammation in SARS-CoV-2 pneumonia 144
Detection and functional evaluation of arginase-1 isolated from human PMNs and murine MDSC 142
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. 140
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy 139
Adipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers 139
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 139
Transcription factors in myeloid-derived suppressor cell recruitment and function. 138
Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. 138
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. 137
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. 132
Nitric oxide furoxan derivative compounds endowed with antitumoral activity 132
New idrosoluble furoxan derivatives having antitumoral activity 131
The cross-talk between myeloid and mesenchymal stem cells of human bone marrow represents a biomarker of aging that regulates immune response and bone reabsorption 131
PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY 128
Myeloid-derived suppressor cell heterogeneity in human cancers 128
Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. 127
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages 125
Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer 123
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. 123
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. 123
Therapeutic targeting of myeloid-derived suppressor cells. 121
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. 121
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. 121
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. 120
Use of myeloid cell biomarkers for the diagnosis of cancer. 119
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. 118
Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. 118
GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment 118
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. 117
Meccanismi molecolari della lisi mediata dai linfociti citotossici 116
Local ablation disrupts immune evasion in pancreatic cancer 115
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. 115
Myeloid-derived suppressor cells generated in vitro 115
Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy 115
Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells 115
Derangement of immune responses by myeloid suppressor cells. 114
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. 114
Role of arginine metabolism in immunity and immunopathology. 113
Interaction of human pancreatic ductal adenocarcinoma cells with polymeric scaffolds to develop tissue-engineered cancer models. 113
Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. 112
Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. 112
Peripheral blood immunophenotyping in a large cohort of patients with Shwachman-Diamond syndrome 112
Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients 111
Role of adhesion molecules in the immune reaction to M-MSV-induced tumors. 110
Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion 109
Smoothing T cell roads to the tumor: Chemokine post-translational regulation. 109
Nitric oxide affects immune cells bioenergetics: long-term effects of nitric-oxide derivatives on leukaemic Jurkat cell metabolism 109
The pros and cons of chemokines in tumor immunology 109
Complexity and challenges in defining myeloid-derived suppressor cells 109
Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs) 108
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. 108
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. 108
Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. 108
Totale 15.000
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.549
article - articoli 82.781
book - libri 0
conference - conferenze 1.796
curatela - curatele 0
other - altro 1.474
patent - brevetti 1.721
selected - selezionate 0
volume - volumi 4.777
Totale 185.098
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021797 0 0 0 0 0 164 23 132 151 37 203 87
2021/20221.735 106 442 31 52 74 47 70 111 115 89 151 447
2022/20232.728 257 262 303 445 230 632 42 154 294 14 57 38
2023/20241.516 63 98 101 192 209 236 66 140 16 87 239 69
2024/20254.793 275 271 146 710 273 163 330 306 828 281 354 856
2025/20267.835 995 635 782 1.783 2.807 833 0 0 0 0 0 0
Totale 26.596